Glycologix Inc. is an emerging biotechnology company targeting locally delivered biopolymers for the protection of soft tissues. Multiple unmet medical conditions can be addressed by replenishment of naturally occurring proteoglycans. Our platform discovery engine enables the preparation of synthetic structural mimics of proteoglycans. Despite their high molecular weight, these novel materials are are highly soluble, enabling optimal tissue coverage. Focused indications for the platform include interstitial cystitis, dry eye, post-surgical adhesion prevention, osteoarthritis, spinal disk disease, and wound repair. Glycologix is supported in part by grants from the NIH.